$NAMS
NewAmsterdam Pharma Company N.V., a clinical-stage biopharmaceutical company, focuses on improving patient care in populations with metabolic diseases. Its lead investigational candidate, obicetrapib, is a novel, selective inhibitor that targets the Cholesteryl Ester Transfer Protein (CETP), which has been clinically shown to reduce low-density lipoprotein cholesterol (LDL-C) while at the same time substantially increase high-density lipoprotein cholesterol (HDL-C). The company was founded in 2019 and is based in Naarden, the Netherlands.
Healthcare
Sector
Biotechnology
Industry
Michael Harvey Davidson Facp.
CEO
68
Employees
$29.62
Current Price
$3.93B
Market Cap
Insider Activity Statistics
Aggregated buying and selling activity by time period
| Period | Type | Insiders | Transactions | Value | Shares | Buy/Sell Ratio |
|---|---|---|---|---|---|---|
| 1 week | Buys | 0 | 0 | - | - | - |
| Sells | 0 | 0 | - | - | ||
| 2 weeks | Buys | 0 | 0 | - | - | - |
| Sells | 0 | 0 | - | - | ||
| 1 month | Buys | 0 | 0 | - | - | - |
| Sells | 0 | 0 | - | - | ||
| 2 months | Buys | 0 | 0 | - | - | - |
| Sells | 0 | 0 | - | - | ||
| 3 months | Buys | 0 | 0 | - | - | All Sells |
| Sells | 3 | 16 | $38,211,395.05 | 1,168,286 | ||
See activity going back 12 months โ create a free account | ||||||
Insider Transactions
Recent purchases and sales by company insiders
| Date | Insider | Type | Shares | Price | Value | Actions |
|---|---|---|---|---|---|---|
| Mar 11, 2026 | LANGE LOUIS G Director | Sale | 446 | $31.23 | $13,928.58 | View Details |
| Mar 11, 2026 | LANGE LOUIS G Director | Sale | 44,173 | $30.41 | $1,343,300.93 | View Details |
| Mar 6, 2026 | LANGE LOUIS G Director | Sale | 28,186 | $29.41 | $828,950.26 | View Details |
| Mar 5, 2026 | Kastelein Johannes Jacob Pieter Director | Sale | 104,467 | $30.30 | $3,165,350.10 | View Details |
| Mar 9, 2026 | Kastelein Johannes Jacob Pieter Director | Sale | 101,409 | $30.29 | $3,071,678.61 | View Details |
| Mar 6, 2026 | Kastelein Johannes Jacob Pieter Director | Sale | 94,124 | $30.32 | $2,853,839.68 | View Details |
| Mar 2, 2026 | Davidson Michael H. Director | Sale | 443,707 | $33.25 | $14,753,257.75 | View Details |
| Feb 25, 2026 | Davidson Michael H. Director | Sale | 1,300 | $36.68 | $47,684.00 | View Details |
| Feb 26, 2026 | Davidson Michael H. Director | Sale | 165,408 | $33.63 | $5,562,671.04 | View Details |
| Feb 26, 2026 | Davidson Michael H. Director | Sale | 17,924 | $34.44 | $617,302.56 | View Details |
| Feb 25, 2026 | Davidson Michael H. Director | Sale | 46,517 | $35.11 | $1,633,211.87 | View Details |
| Feb 24, 2026 | Davidson Michael H. Director | Sale | 61,547 | $36.13 | $2,223,693.11 | View Details |
| Feb 24, 2026 | Davidson Michael H. Director | Sale | 3,161 | $36.46 | $115,250.06 | View Details |
| Feb 25, 2026 | Davidson Michael H. Director | Sale | 10,436 | $35.96 | $375,278.56 | View Details |
| Feb 20, 2026 | Kastelein Johannes Jacob Pieter Director | Sale | 30,789 | $35.46 | $1,091,777.94 | View Details |
| Feb 20, 2026 | Kastelein Johannes Jacob Pieter Director | Sale | 14,692 | $35.00 | $514,220.00 | View Details |
35 more transactions available โ create a free account to see 12 months of history | ||||||
Upcoming Earnings
Scheduled earnings reports
No upcoming earnings scheduled
Past Earnings
Historical earnings results
EPS
Estimated-$0.43
ActualN/A
Revenue
Estimated$920.44K
ActualN/A
EPS
EstimatedN/A
ActualN/A
Revenue
EstimatedN/A
ActualN/A
EPS
Estimated-$0.40
ActualN/A
Revenue
EstimatedN/A
ActualN/A
EPS
Estimated-$0.40
Actual-$0.63
Miss
Revenue
Estimated$920.44K
Actual$32.00K
Miss
2 more earnings records available โ create a free account to see 12 months of history
Related Activity
Cross-company insider connections and cluster buy signals
Insiders Also Active At
Insiders at this company also hold positions or have traded at these companies: